Circulation Journal
Online ISSN : 1347-4820
Print ISSN : 1346-9843
Heart Failure
Vidarabine, an Anti-Herpes Virus Agent, Protects Against the Development of Heart Failure With Relatively Mild Side-Effects on Cardiac Function in a Canine Model of Pacing-Induced Dilated Cardiomyopathy
Takashi NakamuraTakayuki FujitaMegumi KishimuraKenji SuitaYuko HidakaWenqian CaiMasanari UmemuraUtako YokoyamaMasami UechiYoshihiro Ishikawa
Author information
JOURNALS FREE ACCESS FULL-TEXT HTML

Volume 80 (2016) Issue 12 Pages 2496-2505

Details
Full Text-HTML Download PDF (2833K) Contact us
Abstract

Background:In heart failure patients, chronic hyperactivation of sympathetic signaling is known to exacerbate cardiac dysfunction. In this study, the cardioprotective effect of vidarabine, an anti-herpes virus agent, which we identified as a cardiac adenylyl cyclase inhibitor, in dogs with pacing-induced dilated cardiomyopathy (DCM) was evaluated. In addition, the adverse effects of vidarabine on basal cardiac function was compared to those of the β-blocker, carvedilol.

Methods and Results:Vidarabine and carvedilol attenuated the development of pacing-induced systolic dysfunction significantly and with equal effectiveness. Both agents also inhibited the development of cardiac apoptosis and fibrosis and reduced the Na+-Ca2+exchanger-1 protein level in the heart. Importantly, carvedilol significantly enlarged the left ventricle and atrium; vidarabine, in contrast, did not. Vidarabine-treated dogs maintained cardiac response to β-AR stimulation better than carvedilol-treated dogs did.

Conclusions:Vidarabine may protect against pacing-induced DCM with less suppression of basal cardiac function than carvedilol in a dog model. (Circ J 2016; 80: 2496–2505)

Information related to the author
© 2016 THE JAPANESE CIRCULATION SOCIETY
Previous article Next article
feedback
Top